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Summary
Objective: To determine the effects of interleukin (IL)-6 and oncostatin M (OSM) added separately or in combination with IL-1b on human
osteoarthritic (OA) chondrocytes in alginate beads.
Design: Human chondrocytes were isolated from OA cartilage and cultured in alginate beads for 12 days, in the absence or in the presence of
increasing amounts of IL-6 (20e500 ng/ml) with its soluble receptor or OSM (0.1e10 ng/ml) and with or without IL-1b (1.7 ng/ml). Aggrecan
(AGG), transforming growth factor-b1 (TGF-b1), stromelysin-1 [matrix metalloprotease (MMP)-3], tissue inhibitor of metalloproteinases-1
(TIMP-1), macrophage inﬂammatory protein-1 beta (MIP-1b), IL-6 and IL-8 productions were assayed by speciﬁc enzyme ampliﬁed sensitivity
immunoassays. Prostaglandin (PG)E2 was measured by a speciﬁc radioimmunoassay and nitrite (NO2
) by a spectrophotometric method
based upon the Griess reaction.
Results: OSM, but not IL-6, decreased basal AGG and TGF-b1 synthesis. Although IL-6 stimulated basal TIMP-1 production, it did not
signiﬁcantly modify MMP-3/TIMP-1 ratio. In contrast, 10 ng/ml OSM highly increased TIMP-1 production, and decreased by half the ratio
MMP-3/TIMP-1. IL-1b highly stimulated cNO, IL-8, IL-6, MIP-1b and PGE2 synthesis but decreased AGG and TGF-b1 production. Neither IL-6
nor OSM modulated IL-1b-inhibitory effect on AGG production. IL-6, but not OSM, reversed IL-1b-induced TGF-b1 inhibition. At 1e10 ng/ml,
OSM signiﬁcantly decreased IL-1b-stimulated IL-8, MIP-1b, PGE2 and
cNO production but ampliﬁed IL-1b stimulating effect on IL-6 production.
IL-6 had no effect on these parameters.
Conclusions: OSM and IL-6, two glycoprotein 130 binding cytokines, show different activity proﬁles on OA chondrocytes, indicating that these
cytokines could play different roles in the OA disease process.
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Cartilage
Repair
SocietyOsteoarthritis (OA) is a complex disease characterized by
bone remodelling, synovium inﬂammation and cartilage
loss1,2. The physiopathological mechanisms leading to
cartilage degradation have been largely investigated. They
primarily involved an excessive production of metallopro-
teases by the chondrocytes and the neighbouring cells3e5.
In vitro, metalloprotease production is mainly up-regulated
by interleukin (IL)-1b, a cytokine found to be elevated in OA
cartilage6. Furthermore, IL-1b inhibits the synthesis of
cartilage matrix components [aggrecan (AGG) and type II
collagen]7,8 and then reduces the repair capacity of
cartilage. It also stimulates the synthesis of pro-inﬂamma-
tory cytokines [IL-6, IL-8, macrophage inﬂammatory pro-
teins (MIP),.] and reactive oxygen species (cNO, O2
,
H2O2), which both contribute to cartilage degradation and
synovium inﬂammation9e11.
Because IL-6 is one of the most abundant cytokines
found in OA joint, its regulatory action might be very
important in the physiopathology of this disease. Although
IL-6 was demonstrated to increase tissue inhibitor of
metalloproteinases-1 (TIMP-1)12, transforming growth
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cytes, this cytokine is commonly presented as a co-factor of
the catabolic effects of IL-1b. IL-6 enhanced the production
of matrix metalloprotease (MMP)-1315,16 and as a conse-
quence the IL-1b-induced degradation of proteoglycan in
cartilage explants17. More recently, it was reported that IL-6
in the presence, but not in the absence, of its soluble
receptor IL-6sR, acted synergically to IL-1a on cartilage
collagen breakdown18. IL-6sR is a 50e55 kDa glycoprotein
derived from the membrane anchored 80 kDa glycoprotein.
The mechanisms that regulate IL-6sR production are not
clearly understood, but in contrast to most other soluble
cytokine receptors, IL-6sR together with its ligand IL-6 acts
agonistically on cells that express the 130 kDa glycoprotein,
thereby mediating the biological activity of IL-619. IL-6sR is
produced in high amounts by hepatocytes but not by the
structural cells in the joint, including chondrocytes20. Thus,
to mimic the in vivo action of IL-6, a quantity of IL-6sR
similar to that found in serum and synovial ﬂuid of normal or
OA patients should be added in the in vitro experi-
ments12,21.
Oncostatin M (OSM), a 28 kDa cytokine produced by
activated T cells and macrophages, is structurally and
functionally related to the IL-6 cytokine family. OSM is found
to be elevated in synovial ﬂuids of Rheumatoid Arthritis
(RA) patients22. Further, OSM level correlates with those of
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OSM might be an actor in cartilage degradation23.
Nevertheless, its role in synovium inﬂammation and
cartilage degradation is controversial. Findings of a number
of in vivo studies support a predominant pro-inﬂammatory
and catabolic proﬁle, whereas those of other studies
suggest a protective action24e26. Although OSM up-
regulates a spectrum of protease inhibitors, including the
speciﬁc tissue metalloprotease inhibitors (TIMPs) and
serine protease inhibitors (a1-protease inhibitor, anti-chy-
motrypsin and plasminogen activator inhibitor 1)22,27,28, its
catabolic role in arthritis may rely on the up-regulation of the
synthesis of some MMPs22,29,30. Of interest in understand-
ing the role of OSM in arthritis is the capacity of this cytokine
to synergize the action of other inﬂammatory mediators,
such as IL-1, tumour necrosis factor (TNF)-a and IL-17, to
induce the expression of the collagenases, stromelysin,
membrane type 1 MMP, and the aggrecanase ADAM-TS4
but not ADAM-TS522,29,31e33. Further, OSM stimulates the
production of chemokines and prostaglandin (PG)E2, sug-
gesting that OSM might also be an actor in local
inﬂammation34e36.
Therefore, more investigations are needed to clarify the
role of IL-6 and OSM in OA disease processes. Herein, we
have investigated the regulatory action of OSM and IL-6 with
its soluble receptor, on human OA chondrocytes in alginate
beads, a model of culture particularly suitable for studying
cartilage matrix synthesis and formation. We also examined
the effects of these gp130 binding cytokines on the pro-
duction by chondrocytes of numerous soluble factors in-
volved in cartilage degradation and synovium inﬂammation.
Materials and methods
CHONDROCYTE CULTURE IN ALGINATE BEADS
Cartilage was obtained from the knees of cadavers with
primary OA immediately after death, being excised from the
superﬁcial and medium layers of cartilage and avoiding the
calciﬁed layer. Upon dissection, the femoral, patellar and
tibial articular surfaces were evaluated for gross patholog-
ical cartilage modiﬁcations according to a personal scale.
The severity of pitting was recorded for each donor. Four
different grades were considered: 0, normal white cartilage
in all areas examined; I, the presence of a yellow-grey area
with some superﬁcial ﬁbrillations on one or more articular
surfaces; II, irregular surface with deep ﬁbrillations on one
or more articular surfaces; and III, ulcers penetrating to the
subchondral bone on one or more articular surfaces.
Experiments were performed with OA cartilage coming
from three different donors, two males and one female, with
a mean age of 58 (31e81) years. One donor showed OA
cartilage lesions of grade I and the two others, cartilage
lesions of grade III.
Cartilage was cut into small fragments and then
subjected to enzymatic digestion sequentially with hyal-
uronidase, pronase and collagenase (3 g of cartilage per
10 ml of enzyme solution) as described previously37. Cell
viability was estimated by trypan blue exclusion test and in
all cases was greater than 95%. Chondrocytes were
suspended in alginate beads as previously described38
and maintained in culture for 12 days in Duibecco’s
Modiﬁed Eagle Medium (DMEM) supplemented with 1%
ITSC (ICN Biomedicals, Asse-Relegem, Belgium), 10 mM
HEPES, penicillin (100 U/ml) and streptomycin (100 mg/ml),
200 mg/ml glutamine (Biowhittaker Europe, Verviers,Belgium), 50 mg/ml ascorbic acid (SigmaeAldrich, Bornem,
Belgium), and2 mMproline (Invitrogen,Merelbeke,Belgium).
ITSC is a pre-mixed cell growth system containing in 1 ml:
0.625 mg insulin, 0.625 mg transferrin, 0.625 mg selenious
acid, 0.125 g bovine serum albumin (BSA) and 0.535 mg
linoleic acid. Cells remained in this culturemedium (wash-out
medium) for 48 h as a precaution against in vivo contamina-
tion with drugs that donors might have taken before death.
After this wash-out period, culture medium was changed and
the various cytokines were added. Culture medium was
changed every 3 days and the collected supernatants were
kept at 20(C until analysis.
TREATMENTS
Chondrocytes were cultured in ITSC medium (as de-
scribed above) for 12 days in the absence or in the
presence of recombinant human IL-6 (20e500 ng/ml, Bio-
source Europe, Fleurus, Belgium) or OSM (0.1e10 ng/ml,
SigmaeAldrich, Bornem, Belgium) and with or without
1.7 ng/ml recombinant human IL-1b (Roche, Bruxelles,
Belgium). Human IL-6sR (50 ng/ml, recombinant from
R&D systems, Lille, France) was systematically added to
each experiment testing the effects of IL-6. OSM and IL-6
were tested at concentrations covering the range of
concentrations found in the synovial ﬂuid of arthritic
patients. In the same experiment, each culture condition
was performed in triplicate and each experiment was
repeated three times using three different donors.
END OF THE CULTURE
The culture medium (S) was carefully discarded and the
beads were dissolved in 1 ml of 0.1 M citrate for 10 min. The
resulting suspension was centrifuged at 1200 rpm for
10 min. By this method, two fractions were collected: the
supernatant containing macromolecules originated from the
further-removed matrix (FRM) compartment, and a pellet,
containing cells with their associated matrix (CM). These
two fractions were studied separately. The cell pellets were
washed with phosphate buffer saline (PBS, Biowhittaker
Europe, Verviers, Belgium), and then homogenized in 1 ml
of PBS by ultrasonic dissociation at 4(C for DNA assay. CM
and FRM were kept at 20(C until analysis.
DNA ASSAY
The DNA content of the cultures was measured accord-
ing to the ﬂuorimetric method of Labarca and Paigen39.
LACTATE DEHYDROGENASE RELEASE ASSAY
The cell viability was estimated by measuring the amount
of lactate dehydrogenase (LDH) released in the culture
supernatant. In a 96-well plate, 50 ml of Tris 0.01 M buffer,
pH 8.5, containing 0.1% BSA and 800 mM lactate and 50 ml
of a 1.6 mg/ml solution of INT (p-iodonitrotetrazolium violet,
SigmaeAldrich, Bornem, Belgium), 4 mg/ml NAD (Roche
Pharmaceuticals, Brussels, Belgium) and 0.4 mg/ml phen-
azine methosulphate (SigmaeAldrich, Bornem, Belgium)
were added to 100 ml of culture supernatant (before any
freezing). The absorbance at 492 nm was read after 5 min
of incubation at room temperature. The calibration was
performed with LDH isolated from rabbit muscle. The cell
death score was obtained by calculating the ratio (LDH in
supernatants/total LDH)! 100. Total LDH corresponded to
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culture supernatants (0e12 days).
PGE2 RADIOIMMUNOASSAY
PGE2 was assayed in the different compartments (culture
supernatants, FRM and CM) without previous extraction
according to a previously described radioimmunoassay
(RIA)40. In this assay, polyclonal antiserum obtained from
rabbit cross-reacts neither with other prostanoids (TxB2,
6-keto-PGF1a, PGA2) nor with any fatty acids (arachidonic,
linoleic or oleic acids). 3H-labeled PGE2 was purchased
from New England Nuclear (Brussels, Belgium) and the
standard molecule (PGE2) from SigmaeAldrich (Bornem,
Belgium). Intra- and inter-assay coefﬁcients of variation
were 6% and 10%, respectively. The limit of detection of the
RIA was 20 pg/ml.
IMMUNOASSAYS FOR AGG, TGF-b1, MIP-1b, IL-6, IL-8,
MMP-3 AND TIMP-1
AGG, TGF-b1, MIP-1b, IL-6 and IL-8, TIMP-1 and
stromelysin-1 (MMP-3) were measured in the different
culture compartments (S, FRM and CM) by speciﬁc enzyme
ampliﬁed sensitivity immunoassays (EASIA, Biosource
Europe, Fleurus, Belgium). The limits of detection of the
AGG, TGF-b1, MIP-1b, IL-6, IL-8, TIMP-1 and MMP-3
immunoassays were 5.5 ng/ml, 12.5 pg/ml, 12.5 pg/ml,
8 pg/ml, 4 pg/ml, 325 pg/ml and 1.25 ng/ml, respectively.
These assays were based on the oligonal system in
which several monoclonal antibodies were directed against
distinct epitopes of the molecules. In the case of MMP-3,
the antibodies were directed against pro-MMP-3, activated-
MMP-3 and MMP-3 bound to TIMP-1 and TIMP-2. AGG
synthesis was quantiﬁed by an EASIA using a monoclonal
antibody raised against the keratan sulphate region of AGG
as a capture antibody, and a monoclonal antibody to the
hyaluronic acid binding region as a detector. The intra- and
inter-assay coefﬁcients of variation were less than 5% for all
immunoassays.
NITRIC OXIDE (cNO) ASSAY
Nitrite and nitrate are stable end products of nitric oxide.
Nitrate is reduced to nitrite by the addition in the
supernatant of nitrate reductase (0.25 U/ml, Roche Phar-
maceuticals, Brussels, Belgium) for 20 min at 37(C. Nitrite
concentrations in conditioned culture supernatants were
determined by a spectrophotometric method based uponthe Griess reaction41. The absorption was measured at
540 nm. Sodium nitrite (NaNO2) was used for calibration.
CALCULATION AND STATISTICAL ANALYSIS
The results (meanG S.E.M.) were expressed as the
concentration of AGG, TGF-b1, MMP-3, TIMP-1, IL-6,
IL-8, MIP-1b, NO2 and PGE2 in the culture supernatants
(0e12 days), CM and FRM (or the sum of these values for
the total production) per microgram of DNA. A multivariate
repeated measures analysis of variance model with
calculation of contrasts was performed on all the experi-
ments. The concentration-dependency was demonstrated
by calculating the Spearman’s correlation coefﬁcient (r).
Results
EFFECT OF IL-6/IL-6SR AND OSM ON HUMAN OA
CHONDROCYTES
The DNA content (3.7G 0.3 mg per well after 12 days of
culture) increased by 28% over the culture duration, and
was not signiﬁcantly affected by the presence of IL-1b
(1.7 ng/ml), OSM (0.1e10 ng/ml), IL-6sR (50 ng/ml) alone
or combined with IL-6 (20e500 ng/ml). Furthermore, DNA
content was not signiﬁcantly modiﬁed by IL-6 or OSM
added in combination with IL-1b. The cell death, assessed
by the release of LDH from the cells over the culture
duration, ranged from 5% to 7%. None of the experimental
conditions modiﬁed LDH release.
As previously described, newly synthesized AGG were
essentially accumulated in alginate beads38. Sixty-one
percent were found in the FRM, 38% in the CM and only
1% was released in the supernatant. IL-6 (500 ng/ml)/
IL-6sR decreased total AGG production by 20% but did not
modify AGG distribution in the different compartments of the
culture. This inhibitory effect was observable in both
alginate bead and supernatant. Below 500 ng/ml, IL-6 had
no signiﬁcant effect (Table I). OSM decreased in a concen-
tration-dependent manner AGG contents in the alginate
beads (rZ0.9958, PZ 0.0042). However, at the highest
concentration tested (10 ng/ml), the inhibition was more
pronounced in the FRM and as a consequence, the ratio
of AGG accumulated in the FRM was decreased (basal
ratio FRM:CM:SZ 60.5%:38.6%:0.9% vs 10 ng/ml OSMZ
50.3%:48.3%:1.4%).
In the basal conditions, OA chondrocytes produced on
average 49.8G 4.1 pg TGF-b1 per microgram of DNA. This
production was not signiﬁcantly modiﬁed by IL-6 while 0.1, 1Table I
Effects of IL-6/IL-6sR and OSM on basal AGG production and distribution by OA chondrocytes cultured in alginate beads for 12 days
AGG (ng/mg DNA)
FRM CM S Total
Control 3860G 517 2465G 43 57G 7 6386G 567
IL-6 (ng/ml) 0 3897G 354 2440G 222 51G 5 6388G 581
20 3863G 469 2419G 294 51G 6 6333G 769
100 3695G 395 2314G 247 48G 5 6057G 647
500 3176G 202* 1989G 127* 42G 3* 5207G 332*
OSM (ng/ml) 0.1 2871G 215* 1686G 116** 52G 5 4609G 336*
1 1905G 133*** 1420G 68*** 48G 5 3373G 206***
10 1297G 80*** 1246G 69*** 34G 4** 2577G 153***
Values are meansG S.E.M. (NZ 9) of three independent cultures performed with cartilage specimens coming from three different donors.
Statistical signiﬁcance in comparison to the controls: *P! 0.05, **P! 0.01 and ***P! 0.001.
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duction by 23%, 37% and 38%, respectively (P! 0.05,
0.001 and 0.001, rZ0.9794, PZ 0.02, data not shown).
At 500 ng/ml, but not at the lower concentrations, IL-6
slightly increased MMP-3 synthesis [P! 0.01, Fig. 1(A)].
Similarly, at a concentration of 10 ng/ml, but not at the lower
concentrations, OSM stimulated MMP-3 [P! 0.001,
Fig. 1(A)]. TIMP-1 was concentration-dependently en-
hanced by IL-6 and OSM (IL-6: rZ 0.9903, PZ 0.0097;
OSM: rZ 0.8951, PZ 0.05), but the most important effectwas recorded with OSM. At 10 ng/ml, OSM increased by
2.5 times TIMP-1 production [Fig. 1(B)]. The consequence
was a signiﬁcant decrease of MMP-3/TIMP-1 ratio. In the
basal condition, the molar ratio MMP-3/TIMP-1 was equal to
8 but decreased to 4 in the presence of 10 ng/ml OSM
(P! 0.001).
In a range of concentrations between 20 and 500 ng/ml,
IL-6 concentration-dependently inhibited IL-8 production
(rZ0.9815, PZ 0.0185) and stimulated PGE2 produc-
tion (rZ 0.9735, PZ 0.0265), but had no effect on MIP-1b12000
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Fig. 1. Effect of increased concentrations of IL-6C IL-6sR or OSM on basal MMP-3 (A) or TIMP-1 (B) production by human OA chondrocytes.
Values correspond to the total amounts (sum of accumulated amounts found in supernatant, CM and FRM) of MMP-3 or TIMP-1 produced by
chondrocytes during 12 days of culture. Values are meansG S.E.M. (NZ 9) of three independent cultures performed with cartilage specimens
coming from three different donors. Statistical signiﬁcance in comparison to the controls: *P! 0.05, **P! 0.01, ***P! 0.001.
805Osteoarthritis and Cartilage Vol. 12, No. 10and cNO production (Table II). In comparison, OSM was
effective on all these inﬂammatory mediators. In a concen-
tration-dependent manner, it stimulated IL-6 and inhibited
IL-8, MIP-1b and cNO (rZ 0.9708, PZ 0.003; rZ0.9728,
PZ 0.02; rZ0.9850, PZ 0.01 and rZ0.9865, PZ
0.01). At 1 and 10 ng/ml, OSM also inhibited PGE2 pro-
duction by 14% and 16%, respectively. At 0.1 ng/ml, OSM
had no signiﬁcant effect on PGE2 production (Table II).
EFFECTS OF IL-6/IL-6SR AND OSM ON HUMAN OA
CHONDROCYTE RESPONSES TO IL-1b
At a concentration of 1.7 ng/ml, IL-1b inhibited AGG
production (P! 0.001) (data not shown). It decreased by
85% the amount of AGG accumulated in the alginate
beads, and increased by four times the level of AGG
epitopes found in culture supernatant. In the presence of IL-
6sR, IL-1b-inhibitory effect on AGG synthesis was signiﬁ-
cantly accentuated (P! 0.05). No additional effect was
observed when exogenous IL-6 was added to the culture
medium. Whatever the concentration tested, OSM did
not signiﬁcantly modify IL-1b-induced inhibition of AGG
synthesis.
After 12 days of incubation, 1.7 ng/ml IL-1b inhibited
TGF-b1 production by 75%. The addition of 50 ng/ml IL-6sR
partially, but signiﬁcantly, reversed IL-1b-inhibitory effect
(P! 0.001). In the presence of exogenous IL-6
(20e500 ng/ml), basal TGF-b1 production was fully re-
stored [Fig. 2(A)]. On the contrary, OSM had no signiﬁcant
effect on IL-1b inhibition of TGF-b1 production [Fig. 2(A)].
In a previous work42, we have reported that IL-1b
administered every 3 days, increased MMP-3 synthesis
after the ﬁrst 3 days of incubation, but decreased it after 6, 9
or 12 days. During the ﬁrst 3 days of culture, neither IL-6 nor
OSM was able to modify the IL-1b-stimulated MMP-3
production (Fig. 3). After 12 days of culture, IL-6sR
ampliﬁed the inhibitory effect of IL-1b on MMP-3 production
(P! 0.001). The addition of exogenous IL-6 did not modify
IL-1b-inhibitory effect [Fig. 3(A)] whereas 10 ng/ml OSM
partially restored the basal MMP-3 production [P! 0.01;
Fig. 3(B)]. After 12 days of incubation, 1.7 ng/ml IL-1b
decreased TIMP-1 synthesis by 40%. At 0.1 ng/ml, OSM
partially reversed IL-1b-inhibitory effect, but fully restored
basal TIMP-1 production at 1 ng/ml, and even increased
TIMP-1 production over the basal value at 10 ng/ml. On the
contrary, IL-6 acted in synergy with IL-1b to inhibit TIMP-1
[Fig. 2(B)]. The molar MMP-3/TIMP-1 ratio was decreased
by 45% and 32% in the presence of 10 ng/ml OSM and
500 ng/ml IL-6, respectively (0.001! P! 0.01).
At 1.7 ng/ml, IL-1b increased the production of IL-6, IL-8,
MIP-1b, cNO and PGE2 by 7, 11, 26, 2 and 2 times,
respectively. When it was added alone, IL-6sR (50 ng/ml)did not modulate IL-1b-stimulating effects. The addition
of increased amounts of IL-6 did not signiﬁcantly affect
IL-8, MIP-1b or cNO production, but slightly enhanced
IL-1b-stimulated PGE2 production (P! 0.01, data not
shown). OSM signiﬁcantly down-regulated IL-1b-stimulated
PGE2, IL-8, MIP-1b and
cNO production (rZ0.9642,
PZ 0.035; rZ0.9732, PZ 0.027; rZ0.9850, PZ
0.015; rZ0.09873, PZ 0.013), but increased IL-6 in
a concentration-dependent manner (rZ 0.9426, PZ 0.05)
(Fig. 4).
Discussion
In OA, joint tissues undergo structural changes that are
induced by some biochemical factors, which interact to
induce metabolic imbalance. In vitro, IL-1b is considered as
the most potent cytokine to promote the production of
proteolytic enzymes and to inhibit the production of matrix
components43. Nevertheless, recent works have reported
that IL-1b alone induced a modest degradation of cartilage
explants limited to the cleavage of proteoglycan whereas IL-
1b in combination with OSM or IL-6, provoked an earlier and
more marked cleavage of both proteoglycan and collagen
molecules18,32. These in vitro ﬁndings indicate that both IL-6
and OSM play an important regulatory function in cartilage
matrix degradation. Herein, we have described for the ﬁrst
time the effects of OSM and IL-6 on AGG production by
human chondrocytes cultured in alginate beads. This model
is particularly well adapted for studying matrix synthesis and
formation. Newly synthesized AGG are essentially immobi-
lized in alginate bead and distributed around the chondro-
cytes as in the cartilage matrix in vivo44. OSM, but not IL-6,
concentration-dependently inhibited AGG synthesis and
decreased the ratio of AGG accumulated in the FRM. For
the ﬁrst time, these data clearly indicate that OSM, but not
IL-6, acts on cartilage degradation by reducing the repair
capacities of cartilage. In parallel, OSM decreases TGF-b1
synthesis in a concentration-dependent manner, indicating
that the inhibitory effect of OSM on AGG production could
be the result of the TGF-b1 decrease. Indeed, TGF-b1 was
demonstrated to stimulate AGG synthesis by chondro-
cytes45. In OA, extracellular matrix depletion in AGG is not
only the consequence of the decrease of AGG synthesis
but also of the proteolytic action of metalloproteinases,
including stromelysin-1 (MMP-3). MMP-3 activity is directly
controlled by its binding with TIMP-146. The balance of
MMPs and TIMPs is important for tissue remodelling and its
imbalance is believed to play a crucial role in pathophys-
iological processes such as destruction of cartilage and
ﬁbrosis. In our experimental conditions, OSM showed
a modest stimulating effect on basal MMP-3 synthesis butTable II
Effects of IL-6/IL-6sR and OSM on basal inflammatory mediator production by OA chondrocytes cultured in alginate beads for 12 days
IL-6 ( pg/mg DNA) IL-8 ( pg/mg DNA) MIP-1b ( pg/mg DNA) NO2CNO3 (nmol/mg DNA) PGE2 ( pg/mg DNA)
Control 9502G 610 20,577G 1152 30.1G 2.0 38.5G 3.1 167.1G 9.2
IL-6 (ng/ml) 0 N.D. 21,400G 746 34.6G 2.6 36.7G 0.9 170.4G 13.4
20 N.D. 16,873G 1478** 24.1G 5.0 36.5G 0.9 192.2G 11.7
100 N.D. 16,462G 1366** 24.8G 3.9 36.1G 0.3 208.9G 10.0**
500 N.D. 16,050G 476** 28.7G 3.3 39.3G 1.1 225.6G 8.4***
OSM (ng/ml) 0.1 10,583G 501 17,039G 2144 24.9G 3.1 33.3G 2.0 147.5G 5.8
1 13,550G 378*** 11,731G 502*** 21.0G 0.7*** 19.7G 1.3*** 143.8G 3.8**
10 18,545G 686*** 5985G 426*** 15.0G 0.6*** 8.1G 0.4*** 140.9G 7.2**
Values are meansG S.E.M. (NZ 9) of three independent cultures performed with cartilage specimens coming from three different donors.
Statistical signiﬁcance in comparison to the controls: **P! 0.01 and ***P! 0.001.
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human chondrocytes. Values correspond to the total amounts (sum of accumulated amounts found in supernatant, CM and FRM) of MMP-3 or
TIMP-1 produced by chondrocytes during 12 days of culture. They are represented by the meansG S.E.M. (NZ 9) of three independent
cultures performed with cartilage specimens coming from three different donors. Statistical signiﬁcance in comparison to the IL-1b controls:
*P! 0.05, ***P! 0.001.strongly increased basal TIMP-1 production. As a conse-
quence, the molar ratio MMP-3/TIMP-1 was decreased in
the OSM-treated culture. In comparison, IL-6 slightly
increased both basal MMP-3 and TIMP-1 production, but
the ratio MMP-3/TIMP-1 remained unchanged. Since
we know ( personal communication) that the molar ratio
MMP-3/TIMP-1 is elevated in OA chondrocyte culture com-
pared to normal chondrocytes, we can speculate thatOSM acts as a down-regulator of cartilage turnover and
therefore, could contribute to regulate the return to
homeostasis.
In general, IL-1b is presented as the most potent
deregulator of the MMP-3/TIMP-1 balance. It stimulates
MMP-3 synthesis but decreases TIMP-1 production42. In
the alginate bead culture model, IL-1b shows a biphasic
effect on MMP-3 synthesis. After 3 days of incubation, IL-1b
807Osteoarthritis and Cartilage Vol. 12, No. 10Fig. 3. Time- and concentration-dependent effects of IL-6C IL-6sR (A) and OSM (B) on IL-1b-treated (1.7 ng/ml) human OA chondrocytes.
Values correspond to amounts of MMP-3 released in the culture supernatant by chondrocytes during a 3 day culture period (0e3, 3e6, 6e9
and 9e12 days). Values are represented by the meansG S.E.M. (NZ 9) of three independent cultures performed with cartilage specimens
coming from three different donors. Statistical signiﬁcance in comparison to the IL-1b controls: *P! 0.05, ***P! 0.001.stimulates MMP-3 synthesis, but decreases it after 6, 9 and
12 days. On the other hand, IL-1b decreases TIMP-1
synthesis whatever the incubation time, and subsequently
increases the molar ratio MMP-3/TIMP-1 whatever the
culture duration. After 3 days of incubation, neither IL-6 nor
OSM modulates the stimulating effect of IL-1b on MMP-3
synthesis. When the incubation time is prolonged over 3
days, IL-6 synergizes with IL-1b to inhibit MMP-3 while
OSM antagonizes this effect. Again, OSM strongly de-
creases the molar ratio MMP-3/TIMP-1, whereas IL-6 is
without effect.
In experimental animal models, OSM has been reported
to have both inﬂammatory and anti-inﬂammatory effects26.
In experimental animals, intra-articular delivery of OSM or
recombinant adenovirus vectors over-expressing murine
OSM causes joint inﬂammation, synovitis, and struc-
tural damage24,47e49. Blockade of OSM ameliorates jointinﬂammation and cartilage damage in collagen-induced
arthritis25. Inversely, OSM potently suppresses inﬂamma-
tion and tissue degradation in antibody- or bacterial LPS-
induced arthritis in mouse26. One explanation to the anti-
inﬂammatory properties of OSM is given in this work. We
have demonstrated that OSM signiﬁcantly decreased IL-8,
cNO, MIP-1b and PGE2 production by chondrocyte, which
all are factors contributing to synovium inﬂammation. IL-8
and MIP-1b are chemoattractive for macrophages and
neutrophils. MIP-1b is a chemokine found to be elevated in
the synovial ﬂuid of OA compared to normal or RA
patients50. In addition to its ability to stimulate and attract
macrophages, MIP-1b stimulates MMP-3 synthesis by
chondrocytes10. Moreover, IL-8 also stimulates the pro-
duction of peroxides by neutrophils and the exocytosis of
tissue degradative granules at site of inﬂammation51. It is
now well accepted that the release of high levels of PGE2 at
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performed with cartilage specimens coming from three different donors. Statistical signiﬁcance in comparison to the IL-1b controls:
*P! 0.05, ***P! 0.001.the inﬂammatory site stimulates angiogenesis and contrib-
utes to inﬂammatory pain52. cNO was originally identiﬁed as
the endothelium derived relaxing factor with possible pro-
inﬂammatory effects including augmentation of vascular
permeability in inﬂamed tissue53, the generation of de-
structive free radicals such as peroxynitrite and hydroxyl
radical54 and the induction of inﬂammatory cytokines like
IL-1 and TNF-a55. Also of interest in understanding the anti-
inﬂammatory role of OSM is the capacity of this cytokine to
antagonize the stimulating effect of IL-1b on these in-
ﬂammatory mediators. From these data, we can speculate
that OSM is a mediator of the feedback system controlling
the inﬂammatory response and tissue damage. This
hypothesis is supported by the stimulating effect of OSM
on IL-6. Indeed, we and others have demonstrated that
OSM stimulated IL-6 production56. The systemic release
of IL-6 results in an acute phase response by liver to
down-regulate the inﬂammatory response and re-establish
homeostasis. Locally, IL-6 can induce the production of
TIMP-1, IL-1 receptor antagonist, and the soluble TNF
receptor 5514. All these factors contribute to down-regulate
the inﬂammatory reaction.
In conclusion, our work shows that IL-6 and OSM, which
are two gp130 binding cytokines, have some opposite
effects, suggesting that these cytokines could act at dif-
ferent levels of the OA disease process. OSM is presented
as a potent down-regulator of matrix turnover and bio-
chemical inﬂammation, suggesting that this cytokine
contributes to regulate the return to the joint tissue
homeostasis. IL-6 is particularly active on TGF-b1 pro-
duction, a growth factor which promotes osteophyte
formation and synovium ﬁbrosis. By stimulating this growth
factor production, IL-6 could stimulate the hypertrophic
compensation of joint tissue.Acknowledgements
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